BrickBio Enters into Antibody Drug Conjugate (ADC) Co-Development Partnership with a Large Pharmaceutical Company
BOSTON, Jan. 6, 2021 /PRNewswire/ — BrickBio, the leading company in site-specific bioconjugation for improved therapeutics, has signed a deal with a large pharmaceutical partner to co-develop a therapeutic antibody drug conjugate (ADC). Financials and the split of therapeutic…
Comments Off on BrickBio Enters into Antibody Drug Conjugate (ADC) Co-Development Partnership with a Large Pharmaceutical Company